Most Patients With AD Satisfied With Baricitinib Treatment, Study Says

Based on the Likert scale, most patients with atopic dermatitis (AD) using baricitinib reported being either “satisfied” (76%) or “very satisfied” (18%).

Related Keywords

France ,Germany ,United Kingdom , ,European Medicines Agency ,Abbreviated Treatment Satisfaction Questionnaire ,Itch Numerical Rating Scale ,Atopic Dermatitis Treatment ,Baricitinib ,Ditch Control ,Jak Inhibitors ,